Cell and Gene Therapy Tools, and Reagents: Global Markets
Report Highlights
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Report Includes
- 105 total tables
- An updated overview of the global market for immunoassay-based cell and gene therapy tools and reagents
- Analyses of the global market trends, with historic market revenue for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the market potential for the cell and gene therapy tools and reagents in the life sciences industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of actual market size and revenue forecast for cell and gene therapy tools and reagents in USD million terms, and corresponding market share analysis based on product, application/disease area, end-user, and region
- In-depth information (facts and figures) concerning major market dynamics (DROs), product innovations, clinical trials, and various government regulations affecting the market outlook for cell and gene therapy tools and reagents
- Review of prevalence of infectious disease, metabolic disorders and chronic ailments; along with the recent technological advancements, competitive environment, and the industry value chain analysis
- Coverage of the technological, economic, and business considerations of the prevailing cell and gene therapy tools market, and its vendor landscape
- Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology
- Identification of the companies best positioned to meet the demand for cell and gene therapy in life sciences applications owing to their proprietary technologies, novel product launches, key mergers and acquisition deals, and other strategic advantages
- Descriptive company profiles of the market leading players, including Abcam, Akron Biotech, Adverum Biotechnologies and Avrobio.
Report Scope
The scope of this study encompasses an investigation of cell and gene therapy tools: GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. BCC Research analyzes each tool type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next six years. The current report provides detailed analysis of the market's drivers, challenges and opportunities. The report also covers market projections to 2027 and market share for key market players. The report includes the company profiles of key players with detailed information about business segments, financials, product portfolios and recent developments. The report provides impact analysis of the COVID-19 pandemic on this market.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
Report Metrics | Details |
Base year considered | 2021 |
Forecast period considered | 2022-2027 |
Base year market size | $7.6 Billion |
Market size forecast | $13.8 Billion |
Growth rate | CAGR of 10.6% from 2022 to 2027 |
Units considered | $ Million |
Segments covered | Type, Disease, End User |
Regions covered | North America, Europe, Asia Pacific, and Rest of the World (RoW) |
Key Market Drivers |
|
Companies studied |
|
Report Highlights
The global market for life science tools should grow from $6.5 billion in 2019 to reach $9.0 billion by 2024 at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2019-2024.
Report Includes
- 77 data tables
- An overview of the global market for immunoassay-based cell and gene therapy tools, and reagents within the life sciences industry
- Analyses of the global market trends, with data corresponding to market size for 2017-2019, and projections of compound annual growth rates (CAGRs) through 2024
- Information about in vitro diagnostics (IVD), its background and importance of IVD testing
- Discussion on prevalence of infectious disease, metabolic disorders and chronic ailments as drivers of immunoassay testing market
- Description of recent technologies such as chemiluminescent immunoassays (CLIA), fluorescent immunoassays, multiplex assays and rapid diagnostic technologies
- Evaluation of market potential for immunoassay-based cell and gene therapy tools and reagents, current market size and market forecast, and market share analysis of the leading players engaged
- Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology
- Company profiles of the key market participants, including Bio-Rad Laboratories, Cytiva Life Sciences, Luminex Corp., Millipore Sigma, Thermo Fisher Scientific and STEMCELL Technologies